Importance:
There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19).
Objective:
To describe the clinical characteristics and outcomes of patients with COVID-19 hospitalized in a US health care system.
Design, Setting, And Participants:
Case series of patients with COVID-19 admitted to 12 hospitals in New York City, Long Island, and Westchester County, New York, within the Northwell Health system. The study included all sequentially hospitalized patients between March 1, 2020, and April 4, 2020, inclusive of these dates.
Exposures:
Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by positive result on polymerase chain reaction testing of a nasopharyngeal sample among patients requiring admission.
Main Outcomes And Measures:
Clinical outcomes during hospitalization, such as invasive mechanical ventilation, kidney replacement therapy, and death. Demographics, baseline comorbidities, presenting vital signs, and test results were also collected.
Results:
A total of 5700 patients were included (median age, 63 years [interquartile range {IQR}, 52-75; range, 0-107 years]; 39.7% female). The most common comorbidities were hypertension (3026; 56.6%), obesity (1737; 41.7%), and diabetes (1808; 33.8%). At triage, 30.7% of patients were febrile, 17.3% had a respiratory rate greater than 24 breaths/min, and 27.8% received supplemental oxygen. The rate of respiratory virus co-infection was 2.1%. Outcomes were assessed for 2634 patients who were discharged or had died at the study end point. During hospitalization, 373 patients (14.2%) (median age, 68 years [IQR, 56-78]; 33.5% female) were treated in the intensive care unit care, 320 (12.2%) received invasive mechanical ventilation, 81 (3.2%) were treated with kidney replacement therapy, and 553 (21%) died. As of April 4, 2020, for patients requiring mechanical ventilation (n = 1151, 20.2%), 38 (3.3%) were discharged alive, 282 (24.5%) died, and 831 (72.2%) remained in hospital. The median postdischarge follow-up time was 4.4 days (IQR, 2.2-9.3). A total of 45 patients (2.2%) were readmitted during the study period. The median time to readmission was 3 days (IQR, 1.0-4.5) for readmitted patients. Among the 3066 patients who remained hospitalized at the final study follow-up date (median age, 65 years [IQR, 54-75]), the median follow-up at time of censoring was 4.5 days (IQR, 2.4-8.1).
Conclusions And Relevance:
This case series provides characteristics and early outcomes of sequentially hospitalized patients with confirmed COVID-19 in the New York City area.
Citing Articles
Development and validation of a nomogram to assess the occurrence of liver dysfunction in patients with COVID-19 pneumonia in the ICU.
Wang Z, Zhao L, Xie K
BMC Infect Dis. 2025; 25(1):332.
PMID: 40065225
PMC: 11892215.
DOI: 10.1186/s12879-025-10684-1.
COVID-19 among kidney transplant recipients: evaluating risk factors during the initial phase of the pandemic.
Nowak A, Caldinelli A, Segelmark M, Rydell H, Artborg A, Bellocco R
Clin Kidney J. 2025; 18(3):sfaf030.
PMID: 40052164
PMC: 11883224.
DOI: 10.1093/ckj/sfaf030.
Identifying and Validating Prognostic Hyper-Inflammatory and Hypo-Inflammatory COVID-19 Clinical Phenotypes Using Machine Learning Methods.
Ji X, Guo Y, Tang L, Gao C
J Inflamm Res. 2025; 18:3009-3024.
PMID: 40034687
PMC: 11874972.
DOI: 10.2147/JIR.S504028.
The blood urea nitrogen-to-creatinine ratio is associated with acute kidney injury among COVID-19 patients.
Zhong X, Wang X, Feng X, Yu H, Chen Z, Chen X
Ren Fail. 2025; 47(1):2442049.
PMID: 40033758
PMC: 11881656.
DOI: 10.1080/0886022X.2024.2442049.
Metabolomic characteristics and related pathways in patients with different severity of COVID-19: a systematic review and meta-analysis.
Bi C, He J, Yuan Y, Che S, Cui T, Ning L
J Glob Health. 2025; 15:04056.
PMID: 40019163
PMC: 11869518.
DOI: 10.7189/jogh.15.04056.
Health Preferences in Transition: Differences from Pandemic to Post-Pandemic in Valuation of COVID-19 and RSV Illness in Children and Adults.
Mercon K, Rose A, Cadham C, Gebremariam A, Pike J, Wittenberg E
Children (Basel). 2025; 12(2).
PMID: 40003283
PMC: 11854640.
DOI: 10.3390/children12020181.
Viral and immune profiles during the first wave of SARS-CoV-2 infection in hospitalized patients in Sardinia, Italy.
Venturi G, Gallinaro A, Fortuna C, Pirillo M, Scoglio A, Di Carlo B
Sci Rep. 2025; 15(1):6660.
PMID: 39994243
PMC: 11850715.
DOI: 10.1038/s41598-025-90324-5.
Assessment of asymptomatic fungal infections in COVID-19 positive and COVID-19 negative pneumonia: A comprehensive epidemiological analysis.
Mishra D, Kushwaha P, Gangwar P, Singh A, Singh U
J Family Med Prim Care. 2025; 14(1):401-405.
PMID: 39989565
PMC: 11844988.
DOI: 10.4103/jfmpc.jfmpc_2033_23.
Secondary Hemophagocytic Lymphohistiocytosis in severe COVID-19 - a retrospective cohort study.
Oppenauer J, Clodi-Seitz T, Kornfehl A, Wenisch C, Eibensteiner F, Brock R
Sci Rep. 2025; 15(1):6137.
PMID: 39979496
PMC: 11842849.
DOI: 10.1038/s41598-025-90766-x.
The clinical features and outcomes of diabetes patients infected with COVID-19: a systematic review and meta-analysis comprising 192,693 patients.
Liu K, Liu S, Xu T, Qiao H
Front Med (Lausanne). 2025; 12:1523139.
PMID: 39944495
PMC: 11813781.
DOI: 10.3389/fmed.2025.1523139.
Ventilator-Associated Pneumonia in Intensive Care Units: A Comparison of Pre-Pandemic and COVID-19 Periods.
Hlinkova S, Moraucikova E, Strzelecka A, Mrazova M, Littva V
J Clin Med. 2025; 14(3).
PMID: 39941669
PMC: 11818295.
DOI: 10.3390/jcm14031000.
Binding Antibodies Responses to SARS-COV-2 Infection in Hospitalized Patients and Vaccinated Subjects: A Longitudinal Prospective Observational Study.
Alshahrani M, Aldahhan R, Macadato N, Alkhalifah Z, Tahan M, Alnimr A
Saudi J Med Med Sci. 2025; 13(1):39-46.
PMID: 39936001
PMC: 11809754.
DOI: 10.4103/sjmms.sjmms_282_24.
Combining O High Flow Nasal or Non-Invasive Ventilation with Cooperative Sedation to Avoid Intubation in Early Diffuse Severe Respiratory Distress Syndrome, Especially in Immunocompromised or COVID Patients?.
Petitjeans F, Longrois D, Ghignone M, Quintin L
J Crit Care Med (Targu Mures). 2025; 10(4):291-315.
PMID: 39916864
PMC: 11799322.
DOI: 10.2478/jccm-2024-0035.
'Do-not-intubate' orders in patients assisted by noninvasive respiratory support for acute hypoxaemic failure caused by coronavirus disease 2019; a systematic review and meta-analysis.
Cammarota G, Esposito T, Simonte R, Messina A, Cecconi M, Vaschetto R
Eur J Anaesthesiol Intensive Care. 2025; 2(1):e0018.
PMID: 39916762
PMC: 11783619.
DOI: 10.1097/EA9.0000000000000018.
Pathogenic and periodontal bacteria may contribute to the fatal outcome of critically ill elderly COVID-19 patients.
Madronero L, Calvo E, Coronel-Ruiz C, Velandia-Romero M, Calderon-Pelaez M, Arturo J
Sci Rep. 2025; 15(1):4490.
PMID: 39915668
PMC: 11802917.
DOI: 10.1038/s41598-025-88518-y.
Prevalence and Prognostic Impact of Diabetes Mellitus in Hospitalized COVID-19 Patients: A Monocentric Study From India.
Tripathy N, Jain A, Jain J
Cureus. 2025; 17(1):e76902.
PMID: 39902024
PMC: 11789428.
DOI: 10.7759/cureus.76902.
Predictors of developing severe COVID-19 among hospitalized patients: a retrospective study.
Alkhalifa H, Darwish E, Alsalman Z, Alfaraj A, Alkhars A, Alkhalifa F
Front Med (Lausanne). 2025; 11:1494302.
PMID: 39895823
PMC: 11784616.
DOI: 10.3389/fmed.2024.1494302.
Artificial Intelligence-Based Early Prediction of Acute Respiratory Failure in the Emergency Department Using Biosignal and Clinical Data.
Han C, Jung Y, Park J, Chung W, Yoon D
Yonsei Med J. 2025; 66(2):121-130.
PMID: 39894045
PMC: 11790410.
DOI: 10.3349/ymj.2024.0126.
Co-infection of SARS-CoV-2 and influenza A/B among patients with COVID-19: a systematic review and meta-analysis.
Golpour M, Jalali H, Alizadeh-Navaei R, Rezaei Talarposhti M, Mousavi T, Ghara A
BMC Infect Dis. 2025; 25(1):145.
PMID: 39891054
PMC: 11783914.
DOI: 10.1186/s12879-025-10521-5.
Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow-Up Results of the ANATOLIA-AF Study.
Kocabas U, Ergin I, Sonmez S, Yavuz V, Murat S, Ozdemir I
Clin Cardiol. 2025; 48(1):e70088.
PMID: 39871620
PMC: 11773160.
DOI: 10.1002/clc.70088.